Keyphrases
Randomized Clinical Trial
100%
Clinical Stability
100%
Acute Decompensated Heart Failure
100%
Reduced Ejection Fraction
100%
Liraglutide
100%
Heart Failure
50%
Placebo Groups
37%
Rehospitalization
37%
Left Ventricular Ejection Fraction
37%
Glucagon-like
37%
Hazard Ratio
25%
Placebo
25%
Type 2 Diabetes Mellitus (T2DM)
25%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
25%
Between-group Difference
25%
Time Since Death
25%
Hospitalization
12%
Placebo-controlled
12%
Pathophysiology
12%
Heart Failure with Preserved Ejection Fraction (HFpEF)
12%
Quality of Life
12%
Life Events
12%
Cardioprotection
12%
6-minute Walk Distance (6MWD)
12%
Treatment Assignment
12%
Acute Heart Failure
12%
Cardiac Function
12%
Subgroup Analysis
12%
Patients with Diabetes
12%
Cardiac Structure
12%
Clinical Situation
12%
March 2015
12%
Early Phase Clinical Trials
12%
Cardiac Metabolism
12%
Subcutaneous Injection
12%
Ranking Score
12%
Combined Events
12%
Number of Deaths
12%
Proportional Changes
12%
Global Rankings
12%
Mean Rank
12%
Diabetes Status
12%
Medicine and Dentistry
Congestive Heart Failure
100%
Ejection Fraction
100%
Randomized Clinical Trial
100%
Liraglutide
100%
Placebo
75%
Heart Left Ventricle Ejection Fraction
50%
Glucagon-Like Peptide-1 Agonist
37%
Hazard Ratio
25%
Maturity Onset Diabetes of the Young
25%
Amino Terminal Sequence
25%
Brain Natriuretic Peptide
25%
Clinical Study
12%
Pathophysiology
12%
Quality of Life
12%
Antidiabetic Agent
12%
Acute Decompensated Heart Failure
12%
Subgroup Analysis
12%
Patient with Diabetes
12%
Heart Muscle Metabolism
12%
Subcutaneous Injection
12%
Time of Death
12%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Randomized Clinical Trial
100%
Liraglutide
100%
Placebo
75%
Glucagon Like Peptide 1 Receptor Agonist
37%
Brain Natriuretic Peptide
25%
Non Insulin Dependent Diabetes Mellitus
25%
Clinical Study
12%
Pathophysiology
12%
Acute Heart Failure
12%
Antidiabetic Agent
12%
Subcutaneous Injection
12%
Time of Death
12%